Author's response to reviews

Title: Human T cell Lymphotropic Virus Type 1- associated infective dermatitis in KwaZulu Natal, South Africa

Authors:

Carol Hlela (carol.hlela@uct.ac.za)
Natalie Graham (Natalie.Graham@scionresearch.com)
Ahmed Bhigjee (bhigjee@ukzn.ac.za)
Graham P Taylor (g.p.taylor@imperial.ac.za)
Nonhlanhla P Khumalo (n.khumalo@uct.ac.za)
Anisa Mosam (mosam@ukzn.ac.za)

Version: 4 Date: 16 September 2013

Author's response to reviews: see over
Dear Editor,

BMC Dermatology
11 September 2013

Dear Editor

Re: Revision of “Human T cell lymphotropic virus type 1- associated KwaZulu Natal, South Africa” Ref:

Thank you for the opportunity to revise the manuscript, entitled: “Human T cell Lymphotropic Virus Type 1- associated infective dermatitis in KwaZulu Natal, South Africa”

The main issues raised by the editor have now been addressed and corrections now included in the revised manuscript.

Further, for the specific editors comments responses follow below in red.

We hope the present manuscript is in accordance with your editorial policy.

Sincerely yours,

Red Cross Children’s Hospital, Cape Town, South Africa
Editorial Comments:

1. Further to our request to include a statement regarding patient consent, can you please confirm that the parent or guardian of the children included in the case-series study provided informed consent for publication of this Case Series and the accompanying images.
   Yes, I can confirm that consents for publication of the study and the case series images were provided by both the participants and their guardians to the email address provided below.

2. Could you also forward a copy of a completed patient consent document to hayley.henderson@biomedcentral.com for our records. Please note that we only require between 1-3 completed forms. This document should not be attached to the manuscript file in any way as it is confidential data.
   Thank you. I have sent through a copy of the consents as given by both the participants and their guardians to the email address provided below.

3. Could you please include a Competing Interests section. This should appear after the Conclusions section. Please consider the following questions and include a declaration of competing interests in your manuscript:
   Financial competing interests
   ? In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
   ? Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
   ? Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
   ? Do you have any other financial competing interests? If so, please specify.
   Non-financial competing interests
   ? Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
   Answers to the above questions have been included in the revised manuscript.

4. Could you please also remove Tables 1-2 from the additional files and include these in the main manuscript document. These should appear after the References section. This instruction has been effected in the revised manuscript.

5. Please also ensure that your revised manuscript conforms to the journal style (http://www.biomedcentral.com/info/ifora/medicine_journals). It is important that your files are correctly formatted.
   The current version of the manuscript now conforms to the journal style.